文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

早期使用呋塞米对不同中心静脉压下少尿性急性肾损伤进展的影响:一项回顾性分析

THE EFFECTS OF EARLY-PHASE FUROSEMIDE USE ON THE PROGRESSION OF OLIGURIC ACUTE KIDNEY INJURY ACROSS DIFFERENT CENTRAL VENOUS PRESSURE: A RETROSPECTIVE ANALYSIS.
PubMed 文献 · Shock · 2022-11-15
一句话结论在ICU按尿量标准诊断的早期少尿性AKI患者中,仅当CVP 6-12h≥12 mmHg时,早期呋塞米使用与AKI进展至3期及28天死亡风险降低相关。

本研究基于MIMIC-IV数据库,纳入1180例入ICU后前6小时尿量<0.5 mL/kg/h(符合KDIGO尿量标准1期AKI)且CVP 6-12h在0-30 mmHg的成人患者,探讨诊断AKI后6小时内使用呋塞米(呋塞米6-12h)与AKI进展的关系。主要终点为按尿量标准进展至3期AKI,643例(54.5%)发生进展。多因素分析显示,全队列中呋塞米6-12h与严重分期进展显著相关(OR 0.62,95%CI 0.43-0.90,P=0.011);仅在CVP 6-12h≥12 mmHg亚组中观察到AKI进展风险降低(校正OR 0.40,95%CI 0.25-0.65,P<0.001;IPTW分析OR 0.47,95%CI 0.29-0.76,P=0.002)。该亚组中呋塞米6-12h还与28天死亡风险降低相关(校正OR 0.47,95%CI 0.25-0.92,P=0.026),IPTW分析呈相似趋势(校正OR 0.55,95%CI 0.28-1.10,P=0.092)。作者认为CVP可能作为ICU早期少尿性AKI患者使用呋塞米的指导或参考点。

要点

  • 全队列1180例中643例(54.5%)从1期进展至3期AKI;呋塞米6-12h与进展风险降低相关(OR 0.62,95%CI 0.43-0.90,P=0.011)。
  • 仅在CVP 6-12h≥12 mmHg亚组中,呋塞米6-12h与AKI进展风险降低相关(校正OR 0.40,95%CI 0.25-0.65,P<0.001;IPTW OR 0.47,95%CI 0.29-0.76,P=0.002)。
  • CVP 6-12h≥12 mmHg亚组中,呋塞米6-12h与28天死亡风险降低相关(校正OR 0.47,95%CI 0.25-0.92,P=0.026),IPTW分析呈相似趋势但未达统计学显著(校正OR 0.55,95%CI 0.28-1.10,P=0.092)。
  • 作者认为CVP可能作为ICU早期少尿性AKI患者使用呋塞米的指导或参考点。

适用人群与场景

  • 成人ICU患者,入ICU后前6小时尿量<0.5 mL/kg/h(符合KDIGO尿量标准1期AKI),且CVP 6-12h在0-30 mmHg范围内。
  • 数据来源于Medical Information Mart for Intensive Care IV数据库。

诊断标准与关键阈值

  • AKI诊断依据KDIGO指南尿量标准:入ICU后前6小时尿量<0.5 mL/kg/h即符合1期AKI。
  • 呋塞米6-12h定义为按KDIGO尿量标准诊断AKI后6小时内使用呋塞米。
  • CVP 6-12h定义为按KDIGO尿量标准诊断AKI后6小时内的CVP值,范围0-30 mmHg。

研究设计与关键结果

  • 回顾性分析,最终纳入1180例患者,其中643例(54.5%)从1期AKI进展至3期AKI(按尿量标准)。
  • 全队列多因素分析:呋塞米6-12h与严重分期进展显著相关(OR 0.62,95%CI 0.43-0.90,P=0.011)。
  • 按CVP 6-12h分层后,仅在CVP 6-12h≥12 mmHg亚组中观察到呋塞米6-12h与AKI进展风险降低相关(校正OR 0.40,95%CI 0.25-0.65,P<0.001),IPTW分析证实(OR 0.47,95%CI 0.29-0.76,P=0.002)。
  • CVP 6-12h≥12 mmHg亚组中,呋塞米6-12h与28天死亡风险降低相关(多因素logistic回归校正OR 0.47,95%CI 0.25-0.92,P=0.026);IPTW分析呈相似趋势(校正OR 0.55,95%CI 0.28-1.10,P=0.092)。
  • 敏感性分析证实上述结果的稳健性。

证据类型、等级与局限

  • 证据类型:回顾性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,CVP可能作为ICU早期少尿性AKI患者使用呋塞米的指导或参考点。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Background: Furosemide is a commonly used loop diuretic in critical care. However, its effect on the progression of oliguric acute kidney injury across different central venous pressure (CVP) remains unknown. This study therefore aims to investigate the association between furosemide 6-12h (defined as the use of furosemide within 6 h after the diagnosis of AKI according to the urine output [UO] criteria set by the Kidney Disease: Improving Global Outcomes [KDIGO] guidelines) and the progression of AKI across different CVP 6-12h (defined as CVP within 6 h after the diagnosis of AKI by the KDIGO UO criteria) levels. Methods: Patients involved in this study were identified from the Medical Information Mart for Intensive Care IV database with the following criteria: (i) adults with UO <0.5 mL/kg per hour for the first 6 h upon admission to the intensive care unit (ICU) (meeting stage 1 AKI by UO) and (ii) CVP 6-12h ranging from 0 to 30 mm Hg. From there on, the target primary outcome would be progression to stage 3 AKI by UO among these chosen patients. The secondary outcome was 28-d mortality since ICU admission. The risks of severe-stage AKI progression and 28-d mortality were respectively examined against furosemide 6-12h (vs. without furosemide 6-12h ) within the full cohort and across different subgroups of CVP 6-12h , using multivariate adjusted logistic regression and inverse probability treatment weighting (IPTW). Sensitivity analyses were performed to assess the robustness of our findings. Results: One thousand one hundred eighty patients were ultimately selected for this study, of whom 643 (54.5%) progressed to stage 3 AKI from stage 1 based on the UO criteria by KDIGO. Multivariate analysis showed that furosemide 6-12h is significantly associated with this severe-stage progression within the full cohort (odds ratio [OR] was 0.62 at 95% confidence interval [CI] of 0.43-0.90, P = 0.011). After dividing the patients into CVP 6-12h subgroups according to their CVP during the early phases, lower risk of AKI progression was observed only in furosemide 6-12h application at CVP 6-12h of ≥12 mm Hg (adjusted OR was 0.40 at 95% CI of 0.25-0.65, P < 0.001), as confirmed by the IPTW analysis (OR was 0.47 at 95% CI of 0.29-0.76, P = 0.002). The robustness of these findings was confirmed by sensitivity analyses. In addition, for patients with CVP 6-12h ≥12 mm Hg, furosemide 6-12h is also significantly associated with lower risk of 28-d mortality (adjusted OR was 0.47 at 95% CI of 0.25-0.92, P = 0.026) in the multivariate logistic regression analysis, and there was a similar trend in the IPTW analysis (adjusted OR was 0.55 at 95% CI of 0.28-1.10, P = 0.092). Conclusions: Among the identified early-stage AKI patients in critical care, the use of furosemide was associated only with lower risk of oliguric AKI progression and 28-d mortality within the high CVP group. These findings suggest the potential of CVP as a guidance or reference point in the usage of furosemide among early-stage oliguric AKI patients in the ICU.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Huang H, Hu C, Fu Y, et al. THE EFFECTS OF EARLY-PHASE FUROSEMIDE USE ON THE PROGRESSION OF OLIGURIC ACUTE KIDNEY INJURY ACROSS DIFFERENT CENTRAL VENOUS PRESSURE: A RETROSPECTIVE ANALYSIS. Shock. 2022. PMID: 36377392. doi:10.1097/SHK.0000000000002045

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。